Furthermore, mTOR and EGFR co-inhibition with everolimus and gefitinib has shown limited sensitivity in patients owing to enhanced AR activity and PSA levels [293], providing further rationale for combining AR and PI3K-AKT-mTOR blockade to treat prostate cancer. Here, AKT1 is linked to prostate cancer.